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Abstract
Background. Cholangitis, infection of the bile ducts, is a serious condition that necessitates prompt and efficacious treatment
for a good clinical outcome. A single center retrospective study of cholangitis was conducted to better define the spectrum of
responsible pathogens and their antibiotic sensitivities.
Methods. We studied all patients at our hospital who had cholangitis from January 1998 to June 2004. Patients were
identified by ICD-9 codes and the cause of the cholangitis, the treatment and culture data were noted by review of the medical
record.
Results. Thirty patients presented with cholangitis as noted by the clinical symptoms of jaundice, fever and abdominal pain.
The cause of the biliary obstruction was gallstones in 18 patients, benign biliary strictures in 5 and malignant obstruction in 7.
All the patients with malignant obstruction with cholangitis had stents; there were no cases of cholangitis in malignant
obstruction unless prior instrumentation had been performed. The most common isolates were Enterococcus4E.
coli4Enterobacter4Klebsiella. Sixty-four percent of blood cultures and all but one of the bile cultures grew organisms.
Seventy-two percent of patients had positive blood cultures with at least one resistant organism present and 36% had
organisms resistant to multiple antibiotics. Fifty percent of patients with benign biliary disease and positive blood cultures had
multiple organisms growing in their blood. Three-quarters of the isolates were resistant to one or more antibiotics and one-
quarter of isolates were resistant to three or more antibiotics. Resistant organisms were found regardless of the cause of the
biliary obstruction.
Discussion. For all causes of cholangitis, there is a high incidence of positive blood cultures and a high rate of antibiotic
resistance. For optimal treatment, blood and/or bile cultures should be routinely performed to optimize antibiotic therapy.
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Introduction
Increasingly medical centers guide antibiotic therapy
through the use of hospital antibiotic formularies or
clinical pathways. Review of culture and sensitivity
data in various clinical settings is needed to help guide
these antibiotic choices. While biliary tract infections
are common, cholangitis, infection of the bile ducts, is
less frequently encountered. Cholangitis is associated
with a high mortality making appropriate and prompt
treatment important to improve outcome.
Cholangitis involves both obstruction and infection
of the bile ducts. Usually the bile ducts are sterile.
However, the presence of gallstones within either the
gallbladder or biliary tree is associated with bacterial
colonization of the bile [1]. In patients without stone
disease, previous biliary intervention is associated with
high rates of bacterobilia [2,3]. Under conditions of
normal bile flow, bacteria in the biliary system are of no
clinical significance. Upon bile duct obstruction,
bacteria proliferate within the stagnant bile while
biliary pressures increase. Eventually, the bacteria
presumably translocate into the circulation causing a
systemic infection.
This associated inflammatory response can be quite
severe leading to profound sepsis. The impressive
presentation of these toxic patients underscores
the importance of appropriate antibiotic therapy at the
time of presentation. Much of the data on bacterial
causes of cholangitis is dated and there has been a wide
range of proposed antibiotics for the treatment of
biliary infections. We wished to review our experience
with cholangitis, focusing on characterization of the
bacterial pathogens and antibiotic sensitivities. A single
center retrospective review of cholangitis was conduc-
ted to better define the clinical presentation and spec-
trum of pathogens responsible for bile duct infections
to better guide future antibiotic therapies.
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Methods
Patients with cholangitis were identified through
search of ICD-9 codes 576.1 (Cholangitis) and 576.9
(Bile duct, infection). We examined the charts of all 30
patients with cholangitis who were admitted to Ann
Arbor VAMC between 1 January 1 1998 to 1 June
2004. Cholangitis was confirmed with the presence of
jaundice, fever, abdominal pain, and biochemical and
radiographic evidence of biliary obstruction. Data
obtained included: demographic information (age,
sex), clinical presentation (complaints and lab values),
radiographic evaluation (diagnosis and treatment),
clinical history (comorbidities and history of previous
biliary disease, etc.), bile and blood culture results,
surgical course, and long-term follow-up data. This
study was reviewed and approved by our Institutional
Human Subjects Review Board.
Clinical characteristics were compared using
Fisher’s exact test for dichotomous variables and the
Wilcoxon rank-sum test for continuous variables.
Statistical analysis was performed using SAS v.8.0
(SAS Institute, Cary, NC). Data is expressed as
value+standard deviation.
Results
The median patient age was 70 years with a range of
49–87 years old. The mean follow-up was 18 months.
All but one of the patients were male. The cause of the
biliary obstruction was gallstones in 18 patients, benign
biliary strictures in 5 and malignant obstruction in 7.
All three groups of patients had elevated white blood
cell count and bilirubin (Table I). Data in Table I are
expressed as mean+standard error of the mean
(SEM). The serum bilirubin, alkaline phosphatase and
white blood cell counts were similar regardless of the
type of obstruction. The serum glutamic-oxaloacetic
transaminase or [SGOT] levels were significantly
lower with benign biliary strictures and cholangitis.
The significance of this is unclear and may be related to
the fact that this group had the smallest number of
patients. The possibility exists that this group may have
had less hepatocellular damage with the biliary
obstruction than the other two, yet more patients
would need to be studied for any conclusions to be
drawn. The poor overall medical condition of the
majority of patients with cholangitis in this series is
exemplified by the fact that only 13% had no significant
medical comorbidity (Table II).
There was a 13% 30-day mortality for all patients
with cholangitis. The 30-day mortality was high
regardless of the cause of the biliary obstruction (11%
for stone disease, 20% for benign strictures and 29%
for malignant obstruction). One patient presented with
a liver abscess at the time of initial presentation with
cholangitis. Forty-three percent (13) of the patients
died during the period of follow-up. Of those who died,
there was a mean survival from time of diagnosis of
cholangitis to death of 4 months. All of the patients
with malignant biliary obstruction died. Of the six
patients with malignancies, three had Stage IV
pancreatic cancer, three had unresectable hilar
cholangiocarcinoma (Klatskin tumors with two being
Stage III and one Stage IV), and one patient had gall-
bladder cancer with liver metastasis (Stage IV). Six
patients died who did not have a malignant biliary
obstruction, and three of these deaths were directly
related to cholangitis.
Ninety percent (27) of patients underwent ERCP.
Many patients had multiple ERCPs and a total of 52
were done on this group of 30 patients. Forty-four
percent (8/18) of the patients with gallstone disease
had a stent placed at the initial ERCP and later had
stone extraction and sphincterotomy. Six patients went
on to have a percutaneous transhepatic cholangio-
catheter (PTC) placed (several due to unsuccessful
attempts at ERCP and several due to the location of
biliary obstruction).
Thirty percent (9) of patients had significant
hemodynamic instability and a prolonged ICU course
related to the biliary obstruction. Five patients with
choledocholithiasis had a cholecystectomy in the
distant past. Twelve patients who had choledocho-
lithiasis were referred for surgery. One refused, three
had a laparoscopic cholecystectomy, two had a
Table I. Clinical presentation of cholangitis
CBD
stones
Benign
stricture
Malignant
stricture
All
cholangitis
Age (years+SEM) 69+3 65+3 71+4 69+2
Fever (4101.6F) 67% 80% 71% 77%
Abdominal Pain 78% 50% 71% 70%
Jaundice (Bili44) 72% 60% 67% 69%
Vomiting 33% 0% 57% 37%
Hypotension 33% 25% 29% 30%
WBC
(r1000+SEM)
17.8+3.1 16.1+1.8 16.6+1.4 17.2+1.9
Bili (mg/dl) 6.1+0.9 4.6+1 5.7+1.6 5.8+0.7
Alk Phos (U/l) 370+51 472+149 533+87 421+45
SGOT (U/l) 190+35 54+3* 184+61 165+26
* p50.05 compared to CBD stone, malignant stricture, and all
cholangitis groups.
Table II. Medical comorbidities in patients with cholangitis
Medical comorbidities Percent of patients
Hypertension 57%
Cardiac disease 40%
Diabetes 37%
Malignancy (non-biliary) 33%
Pulmonary disease 17%
Renal failure 17%
Liver disease 13%
Vascular disease 10%
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laparoscopic converted to open cholecystectomy, and
two had an open cholecystectomy. Three patients had
an open common bile duct exploration (failed ERCP
removal of stones).
All the patients with malignant obstruction that
presented with cholangitis had stents; there were no
cases of cholangitis in malignant obstruction unless
prior instrumentation had been performed. Seventy-
seven percent (23) of patients had blood cultures at the
time of presentation and 65% (15) of those blood
cultures were positive. Thirty-three percent (10) had
bile cultures and all but one were positive. Multiple
organisms were isolated from the bile and the blood
(Table III). Bile cultures tended to correlate with the
organisms isolated from blood. There was a significant
degree of antibiotic resistance. Seventy-two percent of
patients who had positive blood cultures (8 of 11
patients) had at least one resistant organism present
when sensitivity data was available and 36% of patients
had positive blood cultures with several resistant
organisms present (Table IV). Many isolates were not
sensitive to commonly used antibiotics (Table V).
Statistical analysis revealed no clinically significant
statistical differences between the three groups of
patients.
Discussion
Cholangitis was first described in 1877 by Charcot.
The traditional presentation includes the triad of
jaundice, fever and right upper quadrant pain [4],
though the actual presentation can be quite diverse,
ranging from mild abdominal discomfort to life-
threatening septic shock. In our series, in addition to
fever, abdominal pain and jaundice, the two most
common symptoms included vomiting (33%) and
hypotension (33%). Both biliary obstruction and
bacteria in the bile are required for the development of
cholangitis. In a healthy person, the biliary tree is
normally sterile, but biliary pathology is often asso-
ciated with secondary bacterial colonization [1].
Effective management of cholangitis involves three
steps: appropriate resuscitation, initiation of broad-
spectrum antibiotics to address the systemic infection,
and biliary decompression.
A 5% rate of toxic cholangitis with patients requiring
immediate resuscitation and ICU admission upon
presentation is frequently quoted in the literature [5].
In our series, 30% of patients presented severely toxic
requiring ICU admission. This significant proportion
is likely related to the medical comorbidities (Table II)
in the population of veterans in this series. The medical
comorbidities and mean patient age (69+3 years) also
likely influenced the significant mortality in our series.
The high proportion of males in this series may also be
important. A higher mortality from biliary disease [6]
and a higher conversion rate to open operation in males
[7,8] suggest that biliary disease in the male may be
more virulent, or tends to present later in the course of
the disease. These critically ill patients required
aggressive resuscitation with concurrent management
of their multiple medical comorbidities.
No cancer patients presented with cholangitis with-
out previous stent placement. This reflects the pallia-
tive nature of stents and their well-described high rate
Table III. Bacterial isolates in cholangitis
Organism
Number of Isolates
Blood Bile
Enterococcus faecalis 8 5
E. coli 6 2
Enterobacter cloaca 3 4
Klebsiella pneumoniae 2 3
Streptococcus 3 1
Staphylococcus 2 1
Hemophilus influenza 1 0
Pseudomonas aeriginosa 0 1
Proteus mirabilis 0 1
Citrobacter freundii 0 1
Table IV. Blood culture microbial resistance
Choledocho-
lithiasis
Benign duct
obstruction
Malignant
obstruction
% of patients with blood
cultures
78 75 71
% of patients with positive
culture
64 38 80
% isolates resistant to 1+
antibiotics
75 100 75
% isolates resistant to53
antibiotics
25 0 33
% patients with resistant
organisms to 1+
antibiotics
72 100 75
% patients with resistant
organisms to53
antibiotics
36 0 25
Table V. Antibiotic sensitivities of blood culture isolates
Selected
antibiotics
Gram positive
organisms
Gram negative
organisms
All
organisms
Ampicillin 85% (11/13) 42% (5/12) 64% (16/25)
Amikacin 100% (1/1) 100% (11/11) 100% (12/12)
Aztreonam 100% (1/1) 92% (11/12) 92% (12/13)
Cefazolin 100% (2/2) 64% (7/11) 69% (9/13)
Cefotaxime 100% (5/5) 100% (8/8) 100% (13/13)
Cefotetan Not done 91% (10/11) 91% (10/11)
Ciprofloxacin 67% (6/9) 100% (12/12) 86% (18/21)
Gentamicin 80% (4/5) 100% (12/12) 94% (16/17)
Imipenum 75% (3/4) 100% (11/11) 93% (14/15)
Levofloxacin 83% (5/7) 100% (9/9) 88% (14/16)
Piperacillin Not done 75% (3/4) 75% (3/4)
Pip/Tazo 100% (3/3) 86% (8/9) 92% (11/12)
Ticar/clav Not done 100% (7/7) 100% (7/7)
Tobramycin Not done 100% (9/9) 100% (9/9)
TMP/SMX 50% (1/2) 75% (9/12) 71% (10/14)
Vancomycin 91% (10/11) Not done 91% (10/11)
146 M. J. Englesbe & L. G. Dawes
of occlusion [9]. Stenting for malignant biliary
obstruction is predominantly for advanced surgically
unresectable disease. This was the case for all of the
patients in this series.
Election of the appropriate empiric antibiotic is
critical. Unfortunately, the data most frequently
quoted reflects bacterial data that is old and may not be
applicable to current practice [1,10,11]. Many of the
patients in our series had pathogens in either their bile
or blood that have been well described in cholangitis
(Enterococcus, E. coli, Enterobacter, and Klebsiella)
[12]. Our series showed that even these more common
biliary isolates were often resistant to multiple anti-
biotics. Interestingly, 23% of the bile bacterial isolates
were organisms rarely described in cholangitis (Table
III). Pathogens such as staph aureus, pseudomonas,
and citrobacter may not be covered by routine broad-
spectrum coverage. Antibiotic coverage broad enough
to cover a broad range of organisms should be
considered, especially in patients with biliary stents.
Enterococci and polymicrobial infections are found
more commonly in patients with a biliary stent than in
those without a stent [13]. Polymicrobial infections
were also common in patients with gallstone disease in
this series. Half of the patients with cholangitis from
choledocholithiasis had multiple organisms cultured
from their blood. The polymicrobial nature of
cholangitis along with the high rate of antibiotic resis-
tance for all causes of cholangitis emphasizes the
importance of local antibiotic sensitivity data to guide
clinical pathways involving antibiotic therapy. Blood
cultures are important to guide therapy, especially if
bile cultures are not sent early in the treatment. As in
our study, bile cultures have been shown to correlate
with positive blood cultures in patients with cholangitis
[13,14]. Either blood or bile cultures data can effec-
tively guide antibiotic choices. Often patients are
initially treated with antibiotics, and definitive treat-
ment to relieve biliary obstruction done days later.
Unless a stent is in place, bile cultures may not be
available. In our study only 37% of patients had bile
cultures done and the majority of patients had
indwelling biliary stents. At the time of presentation,
blood cultures are important as one of the initial steps
in the care and treatment of cholangitis.
Antibiotic regimens may vary for different institu-
tions and may be guided by local sensitivity data. For
our institution, a fluoroquinilone or ureidopenicillin
(such as piperacillin with tazobactam) for patients
presenting with cholangitis is a good choice. Fluor-
oquinilones have good biliary excretion even with the
presence of biliary obstruction [15]. There is also a
high percentage of biliary isolates that are sensitive to
this antibiotic. In more complex patients, such as those
who have been extensively exposed to broad-spectrum
antibiotics or those with an endoprostheses, imipenem
or meropenem may be a good choice until culture data
is available. Ampicillin, which has been recommended
as the antibiotic of choice for prophylaxis in biliary
obstruction [13], may not be a good choice for the
treatment of cholangitis given that only about half of
the biliary isolates were sensitive to ampicillin in our
series. Others have seen similar resistance. Likewise,
although cephazolin is often given for prophylaxis in
biliary surgery [16], one third of the bacterial isolates in
our series of cholangitis were resistant to this drug.
Similar to other reports we found a wide variation in
the length of treatment with antibiotics in cholangitis.
Van Lent et al. found that short-duration antibiotic
therapy (3 days) appears sufficient when adequate
biliary drainage is achieved and the patient is clinically
improving [17]. Adequate antibiotic therapy is needed
to avoid sepsis and a need for urgent biliary decom-
pression. Tachycardia, low albumin, high bilirubin and
elevated protime were associated with a higher risk of a
need for emergent ERCP in a prospective study done
by Hui et al. [18]. The choice of antibiotics in reducing
the need for emergent ERCP has not been investigated,
yet given the culture data found by this series and
others, a broader spectrum choice of initial antibiotics
is likely to be more successful in improving outcome.
More important than the length of antibiotic treat-
ment is the early relief of biliary obstruction [19,20].
The etiologies of the bile duct obstruction include:
choledocholithiasis, malignant strictures (cholangio-
carcinoma, pancreatic cancer, ampullary carcinoma),
and benign strictures (pancreatitis, post-operative/
iatrogenic, congenital, or bilio-pancreatic ascariasis).
Common bile duct stones have been the most common
cause in the past (80% in one series and 56% in our
series), but recently the proportion of malignant and
benign strictures has increased [5].
The timing of biliary decompression depends on the
patient’s response to the resuscitation and antibiotics.
In our experience, the sepsis syndrome usually resolves
allowing time for a detailed evaluation of the cause of
the biliary obstruction. If the patient already has an
endoprosthesis, then stent malfunction is very likely. In
patients with choledocholithiasis, ERCP is the diag-
nostic and therapeutic modality of choice [21]. A delay
in biliary decompression in patients who are refractory
to conservative measures has been associated with
increased mortality [19,20]. Various endoscopic
options are available for managing choledocholithiasis,
including endoscopic papillotomy with stone extrac-
tion or placement of a biliary drainage system. In
patients who respond to initial conservative therapy,
papillotomy with stone extraction is preferred, while in
those with ongoing sepsis and multiple large stones, the
placement of a stent is the safest option [22]. If the
patient has no signs of ongoing sepsis and upon ERCP
a lesion is noted that will potentially be managed
operatively, then placement of a stent can complicate
the surgical procedure and should not be placed
without surgical consultation. Percutaneous transhe-
patic biliary catheter placement (PTC) is reserved for
failure of endoscopic drainage and for patients with
suspected hilar cholangiocarcinoma or intrahepatic
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stones. Emergent surgical management of cholangitis
is rarely necessary and should be avoided unless less
invasive modalities (ERCP and PTC) have failed.
Following biliary decompression and patient recov-
ery, surgical management is often necessary to prevent
recurrence of cholangitis, though not always effective.
Four patients presented years following cholecys-
tectomy with primary choledocholithiasis. Treatment
of cholangitis with ERCP and spincterotomy alone,
without cholecystectomy, may be appropriate in indi-
viduals who are a high surgical risk. The risk of recur-
rent biliary infection is high after ERCP with
sphincterotomy alone. All but four patients with
choledocholithiasis in our series were referred for
surgery. The patients not referred for surgery had other
malignancies and/or severe medical comorbidities.
The majority of the patients with gallstones subse-
quently had a cholecystectomy. One patient refused
cholecystectomy and had recurrent biliary symptoms
months later. Unless there is a prohibitive surgical risk,
an elective cholecystectomy is recommended once the
clinical condition stabilizes in patients with cholangitis.
Most studies have shown recurrent symptoms in one-
quarter to one-third of patients if the gallbladder is left
in situ for stone related cholangitis [21,23]. Exceptions
to this may be patients who no longer have any
evidence of residual gallstones or in populations where
primary bile duct stones are prevalent [24]. Due to the
high morbidity and mortality associated with cholan-
gitis, we feel in patients with cholangitis due to stone
disease, cholecystectomy should be performed unless
other medical conditions predict a short survival or
there is a prohibitive surgical risk.
In conclusion, cholangitis is an infectious disease of
the biliary system with associated biliary obstruction.
The cornerstones of therapy include resuscitation,
broad-spectrum antibiotics, and biliary decompres-
sion. Polymicrobial infections are common. Atypical
biliary pathogens should be considered in complex and
critically ill patients with cholangitis, especially when a
biliary stent is present. Initial antibiotic therapy should
include a more intensive regimen than those suggested
for biliary tract infection prophylaxis. Given the
prevalence of antibiotic resistance, blood and/or bile
cultures are important to ensure effective antibiotic
therapy for patients with cholangitis.
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